Skip to main content
    I

    Insight Molecular Diagnostics Inc. (IMDX)

    Official site

    HEALTHCARE • DIAGNOSTICS & RESEARCH • NASDAQ

    $1.86
    -0.28 (-13.08%)

    Market Cap: $70.03M

    Last updated: Nov 17, 2026 at 11:06 AM ET

    Insight Molecular Diagnostics Inc. (IMDX) Stock Forecast

    Updated Nov 17, 2026. Estimates and ratings come from consensus analyst data.

    Analysts expect Insight Molecular Diagnostics (IMDX) to earn -$0.93 per share in the fiscal year ending Dec 31, 2026, on revenue of $966200. Of 5 analysts, 3 rate the stock Buy or Strong Buy, 2 Hold and 0 Sell or Strong Sell, for a consensus of Buy. Over the last 30 days, 1 estimate for the fiscal year ending Dec 31, 2026 was revised up and 0 down.

    Analyst Ratings

    Scoring Strong Buy as 1 and Strong Sell as 5, the 5 ratings average 2.20, inside the Buy band from 1.5 up to 2.5. Buy and Strong Buy make up 60% of the ratings.

    RatingAnalystsShare
    Strong Buy120.0%
    Buy240.0%
    Hold240.0%
    Sell00.0%
    Strong Sell00.0%
    Consensus
    Buy
    Total analysts
    5

    Price Target

    Analyst price targets are part of paid GNG plans. See plans

    Annual Estimates

    From the first fiscal year below to the second, the EPS consensus shows a smaller loss and revenue estimates rise 589.3%.

    Fiscal year ending Dec 31, 2026
    -$0.93
    EPS consensus, revenue $966200
    Fiscal year ending Dec 31, 2027
    -$0.80
    EPS consensus, revenue $6.66M
    Next report
    Mar 24, 2027
    Estimated

    EPS range

    Revenue range

    Fiscal year endingEPS consensusEPS rangeEPS analystsRevenue consensusRevenue rangeRev. analysts
    Dec 31, 2026-$0.93-$0.93 to -$0.922$966200$400000 to $1.70M5
    Dec 31, 2027-$0.80-$0.84 to -$0.762$6.66M$1.01M to $11.90M5

    Quarterly Estimates

    Quarter endingEPS consensusEPS rangeEPS analystsRevenue consensusRevenue rangeRev. analysts
    Dec 31, 2026-$0.24-$0.24 to -$0.237$477156$98000 to $1.16M7

    Estimate Revisions

    Across the 2 periods below, the last 30 days brought 1 upward and 1 downward EPS revisions.

    PeriodUp 30 daysDown 30 days
    Fiscal year ending Dec 31, 202610
    Fiscal year ending Dec 31, 202701

    EPS Trend

    Over the last 90 days, the EPS consensus for the fiscal year ending Dec 31, 2026 has worsened from -$0.85.

    PeriodNow7 days ago30 days ago60 days ago90 days agoChange
    Fiscal year ending Dec 31, 2026-$0.93-$0.93-$0.93-$0.93-$0.85N/A
    Fiscal year ending Dec 31, 2027-$0.80-$0.80-$0.80-$0.84-$0.78N/A

    Frequently Asked Questions About IMDX

    What is the IMDX stock forecast?

    Consensus analyst estimates put Insight Molecular Diagnostics's EPS at -$0.93 for the fiscal year ending Dec 31, 2026, on revenue of $966200. The consensus rating from 5 analysts is Buy.

    How do analysts rate IMDX stock?

    Of 5 analysts covering Insight Molecular Diagnostics, 1 rates it Strong Buy, 2 Buy, 2 Hold, 0 Sell and 0 Strong Sell, for a consensus of Buy.

    What EPS do analysts expect from IMDX next year?

    For the fiscal year ending Dec 31, 2026, the consensus EPS estimate is -$0.93, with estimates from -$0.93 to -$0.92 from 2 analysts. For the fiscal year ending Dec 31, 2027, the consensus EPS estimate is -$0.80, with estimates from -$0.84 to -$0.76 from 2 analysts.

    What revenue do analysts expect from Insight Molecular Diagnostics next year?

    For the fiscal year ending Dec 31, 2026, the consensus revenue estimate is $966200, with estimates from $400000 to $1.70M. For the fiscal year ending Dec 31, 2027, the consensus revenue estimate is $6.66M, with estimates from $1.01M to $11.90M.

    How many analysts cover IMDX?

    5 analysts rate Insight Molecular Diagnostics stock, and 2 analysts estimate its EPS for the fiscal year ending Dec 31, 2026.